Pfizer to acquire privately held ReViral for up to $525 million

36913 pfizer to acquire privately held reviral for up to 525 million

Pfizer Inc. said Thursday it has agreed to acquire ReViral Ltd., a privately held clinical-stage biotech focused on developing antiviral therapeutics that target respiratory synctial virus, or RSV. “RSV is a respiratory pathogen, which can lead to severe and life-threatening lower respiratory tract infections (LRTIs) in high-risk populations, including young infants, immunocompromised individuals, and older adults,” the company said in a statement. It causes about 64 million infections every year and leads to about 160,000 deaths globally. There are currently only limited treatment options for the illness. Under the…

Source: Marketwatch

Related Posts